Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.

Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C.

Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4592-7. doi: 10.1073/pnas.1113748109. Epub 2012 Mar 5.

2.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW.

Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3.

3.

Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.

Zhang L, Jiao M, Li L, Wu D, Wu K, Li X, Zhu G, Dang Q, Wang X, Hsieh JT, He D.

J Cancer Res Clin Oncol. 2012 Apr;138(4):675-86. doi: 10.1007/s00432-011-1146-2. Epub 2012 Jan 12.

PMID:
22237455
4.

Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.

Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC.

Oncotarget. 2011 Dec;2(12):1155-64.

5.

Cancer immunotherapy comes of age.

Mellman I, Coukos G, Dranoff G.

Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673. Review.

6.

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.

Flies DB, Sandler BJ, Sznol M, Chen L.

Yale J Biol Med. 2011 Dec;84(4):409-21. Review.

7.
8.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

9.

New insights into the T cell synapse from single molecule techniques.

Dustin ML, Depoil D.

Nat Rev Immunol. 2011 Sep 9;11(10):672-84. doi: 10.1038/nri3066. Review.

10.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

11.
12.

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Rosenberg SA.

Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116. Review.

PMID:
21808266
13.

Beyond ipilimumab: new approaches target the immunological synapse.

Garber K.

J Natl Cancer Inst. 2011 Jul 20;103(14):1079-82. doi: 10.1093/jnci/djr281. Epub 2011 Jul 7. No abstract available.

PMID:
21737695
14.

PKC-θ function at the immunological synapse: prospects for therapeutic targeting.

Zanin-Zhorov A, Dustin ML, Blazar BR.

Trends Immunol. 2011 Aug;32(8):358-63. doi: 10.1016/j.it.2011.04.007. Epub 2011 Jul 4. Review.

15.

The role of CD97 in regulating adaptive T-cell responses.

Spendlove I, Sutavani R.

Adv Exp Med Biol. 2010;706:138-48. Review.

PMID:
21618833
16.

Modulation of the dendritic cell-T-cell synapse to promote pathogen immunity and prevent autoimmunity.

Carreño LJ, González PA, Bueno SM, Riedel CA, Kalergis AM.

Immunotherapy. 2011 Apr;3(4 Suppl):6-11. doi: 10.2217/imt.11.38. Review.

PMID:
21524159
17.

Cell surface engineering of mesenchymal stem cells.

Sarkar D, Zhao W, Gupta A, Loh WL, Karnik R, Karp JM.

Methods Mol Biol. 2011;698:505-23. doi: 10.1007/978-1-60761-999-4_35.

PMID:
21431540
18.

Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.

Barr AJ.

Future Med Chem. 2010 Oct;2(10):1563-76. doi: 10.4155/fmc.10.241. Review.

19.

Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.

Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquère K, Badoual C, Damotte D, Validire P, Maubec E, Delongchamps NB, Cazes A, Gibault L, Garcette M, Dieu-Nosjean MC, Zerbib M, Avril MF, Prévost-Blondel A, Randriamampita C, Trautmann A, Bercovici N.

PLoS One. 2011 Mar 7;6(3):e17621. doi: 10.1371/journal.pone.0017621.

20.

Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms.

Sarkar D, Ankrum JA, Teo GS, Carman CV, Karp JM.

Biomaterials. 2011 Apr;32(11):3053-61. doi: 10.1016/j.biomaterials.2010.12.036. Epub 2011 Jan 22.

Supplemental Content

Support Center